77 related articles for article (PubMed ID: 27211532)
1. Multiscale fusion network drives the repurposing of anticancer drugs.
Wan Z; Jiang N; Su M; Zhang X; Cao Y; Wu A; Zhang P; Jiang T
Clin Transl Med; 2024 Jul; 14(7):e1745. PubMed ID: 38924682
[No Abstract] [Full Text] [Related]
2. IRDiRC Drug Repurposing Guidebook: making better use of existing drugs to tackle rare diseases.
Hechtelt Jonker A; Day S; Gabaldo M; Stone H; de Kort M; O'Connor DJ; Pasmooij AMG
Nat Rev Drug Discov; 2023 Dec; 22(12):937-938. PubMed ID: 37872324
[No Abstract] [Full Text] [Related]
3. [Difficulties in developing drugs for rare cancers: the example of sarcomas].
Brahmi M
Rev Prat; 2024 Mar; 74(3):245-246. PubMed ID: 38551856
[No Abstract] [Full Text] [Related]
4. Immunotherapy for Soft Tissue Sarcoma: Tomorrow Is Only a Day Away.
Lee A; Huang P; DeMatteo RP; Pollack SM
Am Soc Clin Oncol Educ Book; 2016; 35():281-90. PubMed ID: 27249707
[TBL] [Abstract][Full Text] [Related]
5. Drug Repurposing by Tumor Tissue Editing.
Lüke F; Harrer DC; Pantziarka P; Pukrop T; Ghibelli L; Gerner C; Reichle A; Heudobler D
Front Oncol; 2022; 12():900985. PubMed ID: 35814409
[TBL] [Abstract][Full Text] [Related]
6. Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases.
Liu Z; Fang H; Slikker W; Tong W
Trends Pharmacol Sci; 2016 Oct; 37(10):843-857. PubMed ID: 27461952
[TBL] [Abstract][Full Text] [Related]
7. Drug repositioning in sarcomas and other rare tumors.
Lee ATJ; Huang PH; Pollack SM; Jones RL
EBioMedicine; 2016 Apr; 6():4-5. PubMed ID: 27211532
[No Abstract] [Full Text] [Related]
8. Computational drug repositioning for rare diseases in the era of precision medicine.
Delavan B; Roberts R; Huang R; Bao W; Tong W; Liu Z
Drug Discov Today; 2018 Feb; 23(2):382-394. PubMed ID: 29055182
[TBL] [Abstract][Full Text] [Related]
9. Repurposing Drugs in Oncology: Next Steps.
Verbaanderd C; Meheus L; Huys I; Pantziarka P
Trends Cancer; 2017 Aug; 3(8):543-546. PubMed ID: 28780930
[TBL] [Abstract][Full Text] [Related]
10. eRepo-ORP: Exploring the Opportunity Space to Combat Orphan Diseases with Existing Drugs.
Brylinski M; Naderi M; Govindaraj RG; Lemoine J
J Mol Biol; 2018 Jul; 430(15):2266-2273. PubMed ID: 29237557
[TBL] [Abstract][Full Text] [Related]
11. Phase II trials of drug combinations: fairytales or fact?
Verweij J
Eur J Cancer; 2005 Jan; 41(2):195-6. PubMed ID: 15661541
[No Abstract] [Full Text] [Related]
12. Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study.
Pasquier E; André N; Street J; Chougule A; Rekhi B; Ghosh J; Philip DSJ; Meurer M; MacKenzie KL; Kavallaris M; Banavali SD
EBioMedicine; 2016 Apr; 6():87-95. PubMed ID: 27211551
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
